Alector (ALEC) - Forward P/S Multiple
Alector, Inc. (ALEC) leads the field of immunoneurology, developing drugs to stimulate the brain's protective functions against neuronal degeneration. The company's modeled P/S visualizes market expectations, with the 1.60 value reflecting the metric's balance. The business targets the global market for Alzheimer's and Parkinson's treatments. Currently, Alector, Inc. (ALEC) is scaling its potential by conducting large-scale clinical trials of innovative therapeutic solutions.
Analytical breakdowns for Alector, Inc.
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
ALEC - Net Income|Expected Profit Alector, Inc.|ALEC - Price to Earnings Multiple|Forward P/E Multiple Alector|ALEC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Alector, Inc.|ALEC - Operating profit EBITDA|Earnings per share for the last twelve months Alector|ALEC - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months alector.com|ALEC - Earnings per share growth rate in current year|Earnings growth forecast for next year Alector, Inc.
- sales and revenue indicators:
Fundamental company analysis:ALEC (Alector Therapeutics)
The resilience of Alector, Inc. (ALEC) is based on the synergy between management's scientific expertise and strategic partnerships in Alzheimer's disease therapy. When analyzing the forward P/S ratio, an investor correlates the current market capitalization with projected revenue to determine the cost of each dollar of expected sales. This metric allows for the identification of overvalued assets, preventing the acquisition of a business at the peak of unjustified expectations regarding clinical programs.
Who Alector, Inc. competes with
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|Market Cap to Expected Sales Ratio Axsome Corp AXSM|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc. (SUPN)|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Market Cap to Expected Sales Ratio Denali Corp|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|TRVI: Price-to-Projected Revenue Ratio|PRAX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Anavex Life Sciences Corp (AVXL)|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prothena Corporation (PRTA)|Price-to-Projected Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Projected Revenue|Forward P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Market Cap to Future Revenue Ratio|VYGR: Forward Price-to-Revenue Multiple|NMRA - Forward P/S Multiple|Scilex (SCLX) - Price-to-Projected Revenue Ratio|Tevogen Bio Holdings Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Alpha Cognition Inc|Market Cap to Future Revenue Ratio Cognition Therapeutics Inc. CGTX|Forward P/S Multiple IKT|Forward P/S Multiple cassavasciences.com (SAVA)|Price-to-Projected Revenue Ratio Assertio ASRT|Coya Therapeutics Inc - Price-to-Projected Revenue Ratio|VistaGen Therapeutics Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ovid Therapeutics Inc.|ABOS: Forward P/S Multiple|Forward Price-to-Revenue Multiple cervomed.com|Forward Price-to-Revenue Multiple ATHE|CLNN (Clene Nanomedicine) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|Forward Price to Sales ANVS|GRCE: Forward Price-to-Revenue Multiple|Forward Price to Sales AIFF (Firefly Neuroscience, Inc.)|KLTO: Forward P/S Multiple|NRSN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Market Cap to Projected Revenue MTVA (MetaVia, Inc.)|Forward P/S Multiple NRXS|Forward Price-to-Revenue Multiple heliusmedical.com HSDT|Passage Bio - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Forward P/S Multiple|ATHA - Forward P/S Multiple|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|ALZN (Alzamend Neuro) - Price-to-Projected Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Protagenic PTIX|Forward P/S Multiple KTTA|Forward Price-to-Revenue Multiple cortigent.com CRGT|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|BCLI: Market Cap to Projected Revenue|Cara Therapeutics, Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Chromocell|ELYM (eliemtx.com) - Forward Price-to-Revenue Multiple|Intra-Cellular Therapies, Inc. (ITCI) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|MRNS: Forward Price to Sales|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO - Market Cap to Future Revenue Ratio|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Forward P/S Multiple synaptogen.com SNPX|TRVN - Price-to-Projected Revenue Ratio|VIGL: Price-to-Projected Revenue Ratio|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
